Abstract:Abstract Persistent Jak/Stat3 signal transduction plays a crucial role in tumorigenesis and immune development. Activated Jak/Stat3 signaling has been validated as a promising molecular target for cancer therapeutics discovery and development. Berbamine (BBM), a natural bis-benzylisoquinoline alkaloid, was identified from the traditional Chinese herbal medicine Berberis amurensis used for treatment of cancer patients. While BBM has been shown to have potent antitumor activities with low toxicity in various cancer types, the molecular mechanism of action of BBM remains largely unknown. Here, we determine the antitumor activities of thirteen synthetic berbamine derivatives (BBMDs) against human solid tumor cells. BBMD3, which is the most potent in this series of novel BBMDs, exhibits over 6-fold increase in biological activity compared to natural BBM. Moreover, BBMD3, directly inhibits Jak2 autophosphorylation kinase activity in vitro with IC50 = 0.69 μM. Autophosphorylation of Jak2 kinase at Tyr1007/1008 sites also was strongly inhibited in the range of 1 μM to 5 μM of BBMD3 in human melanoma cells 4 h after treatment. Following inhibition of autophosphorylation of Jak2, BBMD3 blocked constitutive activation of downstream Stat3 signaling in melanoma cells. BBMD3 also down-regulated expression of Stat3 target proteins Mcl-1and Bcl-xL, associated with induction of apoptosis. In sum, our findings demonstrate that the novel berbamine derivative BBMD3 is an inhibitor of the Jak2/Stat3 signaling pathway, suggesting evidence for a molecular mechanism whereby BBMD3 exerts at least part of apoptosis of human melanoma cells. In addition, BBMD3 represents a promising lead compound for development of new therapeutics for cancer treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 864. doi:1538-7445.AM2012-864

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway

A Novel M Phase Blocker, DCZ3301 Enhances the Sensitivity of Bortezomib in Resistant Multiple Myeloma Through DNA Damage and Mitotic Catastrophe

A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib

A novel phosphoramide compound, DCZ0847, displays <i>in vitro</i> and <i>in vivo</i> anti-myeloma activity, alone or in combination with bortezomib

Dual Inhibition of Mtorc1/2 by DCZ0358 Induces Cytotoxicity in Multiple Myeloma and Overcomes the Protective Effect of the Bone Marrow Microenvironment

DCZ0801, a Novel Compound, Induces Cell Apoptosis and Cell Cycle Arrest Via MAPK Pathway in Multiple Myeloma.

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

Preclinical Activity Of Dcz3301, A Novel Aryl-Guanidino Compound In The Therapy Of Multiple Myeloma

Glycolysis is Suppressed by DCZ0801-induced Inactivation of the Akt/mTOR Pathway in Multiple Myeloma

Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma.

Cmar_a_194202 4797..4808

Dcz0814 Induces Apoptosis And G0/G1 Phase Cell Cycle Arrest In Myeloma By Dual Inhibition Of Mtorc1/2

Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway

A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

Novel Synthetic Derivatives of the Natural Product Berbamine Inhibit Jak2/Stat3 Signaling and Induce Apoptosis of Human Melanoma Cells.

Novel Synthetic Berbamine Derivatives Inhibit Jak2/Stat3 Signaling And Induce Apoptosis Of Human Melanoma Cells

A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory

A Novel Silicone Derivative of Natural Osalmid (DCZ0858) Induces Apoptosis and Cell Cycle Arrest in Diffuse Large B-cell Lymphoma Via the JAK2/STAT3 Pathway